CERS CERUS CORP
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1020214 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY54.2%
TTM EPS YoY50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1.0%
Net margin-2.9%
FCF margin0.2%
EBITDA margin-0.3%
Returns
ROE-10.7%
ROA-3.5%
ROIC (approx.)-3.8%
Asset turnover1.21x
Leverage & solvency
Liabilities / assets62.7%
Debt / equity0.00x
Current ratio1.96x
Interest coverage-0.36x
Cash quality & payout
Operating cash flow / net income-0.48x
Accruals ratio-5.1%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $57.71M | $57.44M | $53.66M | $85.42M | $52.70M | $52.45M | $43.24M | — |
| R&D expense | $14.27M | $14.39M | $14.53M | $16.39M | $15.82M | $18.90M | $16.61M | $15.44M |
| SG&A expense | $21.92M | $22.86M | $19.95M | $20.83M | $18.62M | $21.18M | $20.29M | $19.33M |
| Operating income | $383,000 | -$1.86M | -$354,000 | -$641,000 | $1.24M | -$3.42M | -$5.85M | -$1.45M |
| Interest expense | $1.24M | $1.71M | $1.87M | $1.96M | $2.12M | $2.15M | $2.11M | $2.05M |
| Pretax income | -$514,000 | -$2.89M | -$1.56M | -$2.06M | $65,000 | -$5.64M | -$7.64M | -$2.45M |
| Income tax | $66,000 | $95,000 | $91,000 | $119,000 | $85,000 | $76,000 | $74,000 | $111,000 |
| Net income | -$550,000 | -$2.94M | -$1.64M | -$2.18M | -$19,000 | -$5.71M | -$7.72M | -$2.52M |
| EBITDA | $804,000 | -$1.40M | $93,000 | -$248,000 | $1.62M | -$3.08M | -$5.55M | -$1.12M |
| EPS (basic) | 0.00 | -0.01 | -0.01 | — | 0.00 | -0.03 | -0.04 | — |
| EPS (diluted) | 0.00 | -0.01 | -0.01 | — | 0.00 | -0.03 | -0.04 | — |
| Weighted avg. shares (diluted) | 201.65M | 200.56M | 194.14M | — | 191.83M | 191.30M | 187.07M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $16.35M | $17.98M | $27.85M | $19.96M | $16.81M | $17.13M | $20.59M | $21.36M |
| Short-term investments | $40.76M | $38.28M | $52.58M | $62.92M | $62.84M | $62.03M | $61.44M | $60.19M |
| Receivables | $30.56M | $30.98M | $29.32M | $30.37M | $29.77M | $31.39M | $26.34M | $29.78M |
| Inventory | $64.69M | $65.81M | $61.12M | $56.10M | $53.14M | $54.53M | $48.16M | $38.15M |
| Current assets | $156.57M | $157.31M | $175.34M | $174.38M | $167.13M | $168.53M | $161.51M | $152.02M |
| PP&E, net | $9.42M | $9.41M | $9.25M | $9.20M | $6.58M | $6.89M | $7.05M | $7.15M |
| Goodwill | $1.32M | $1.32M | $1.32M | $1.32M | $1.32M | $1.32M | $1.32M | $1.32M |
| Total assets | $204.73M | $205.19M | $222.91M | $221.86M | $215.19M | $213.07M | $206.78M | $200.92M |
| Current liabilities | $80.01M | $85.79M | $107.38M | $100.80M | $88.43M | $84.36M | $69.69M | $63.61M |
| Total liabilities | $128.37M | $134.47M | $154.62M | $156.89M | $152.98M | $156.90M | $150.53M | $144.02M |
| Shareholders' equity | $75.70M | $70.02M | $67.55M | $64.22M | $61.46M | $55.43M | $55.49M | $56.15M |
| Shares outstanding | — | — | — | 192.14M | — | — | — | 185.77M |
| Cash flow statement | ||||||||
| Operating cash flow | $3.01M | -$2.66M | -$3.05M | $6.20M | $1.93M | -$2.45M | -$844,000 | $4.93M |
| Capital expenditure | $590,000 | $873,000 | $233,000 | $1.31M | $1.83M | $477,000 | $112,000 | $976,000 |
| Free cash flow | $2.42M | -$3.53M | -$3.28M | $4.89M | $94,000 | -$2.92M | -$956,000 | $3.95M |
| Investing cash flow | -$3.41M | $12.87M | $9.86M | -$1.38M | -$2.51M | -$1.09M | -$1.19M | -$7.29M |
| Financing cash flow | -$1.23M | -$20.04M | $1.19M | -$1.03M | $320,000 | -$129,000 | $1.07M | $746,000 |
| Depreciation & amortization | $421,000 | $461,000 | $447,000 | $393,000 | $382,000 | $344,000 | $307,000 | $332,000 |
| Stock-based compensation | $6.10M | $5.50M | $4.90M | $4.93M | $5.62M | $5.68M | $6.63M | $5.50M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.